Gilead to Buy PepStar Drug for $1.28B
Gilead Sciences agreed to acquire PepStar Therapeutics inflammation drug program for $1.28 billion in cash. The transaction adds an early-stage bowel disease candidate to Gilead portfolio and expands its immunology strategy.
Xurve View
Insights:
Xurve View
Gilead Sciences agreed to acquire PepStar Therapeutics' oral inflammation drug program for $1.28B in cash upfront. The deal adds an experimental bowel disease candidate to Gilead's portfolio following positive mid-stage trial results. The acquisition expands the company's immunology pipeline beyond its core HIV business.
